Methylprednisolone vs Dexamethasone Interaction With Sugammadex in Pediatric Patients (NCT07175623) | Clinical Trial Compass
CompletedNot Applicable
Methylprednisolone vs Dexamethasone Interaction With Sugammadex in Pediatric Patients
Turkey (Türkiye)60 participantsStarted 2025-09-16
Plain-language summary
This randomized controlled trial aims to compare the interaction of methylprednisolone and dexamethasone with sugammadex in pediatric patients undergoing adenoidectomy and/or tonsillectomy. The primary objective is to evaluate the effect of these corticosteroids on the reversal time of rocuronium-induced neuromuscular block by sugammadex. Secondary outcomes include postoperative pain, nausea and vomiting, extubation time, and adverse events. Eligible participants are children aged 5 to 12 years, ASA I-II, scheduled for elective surgery under general anesthesia. The study is designed as a triple-blind, parallel-group trial with three arms: methylprednisolone, dexamethasone, and placebo.
Who can participate
Age range
5 Years – 12 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Children aged 5-12 years
* American Society of Anesthesiologists (ASA) physical status I-II
Exclusion Criteria:
* ASA physical status ≥ III
* Emergency surgery
* Known allergy or contraindication to neuromuscular blocking agents, sugammadex, or corticosteroids
* Chronic or recent systemic corticosteroid use (within the last 3 months)
* Neuromuscular disorders (e.g., muscular dystrophy, myasthenia gravis)
* Severe hepatic or renal dysfunction
* Significant respiratory or cardiac disease
* Anticipated difficult airway or history of difficult intubation
* Developmental delay or craniofacial anomalies affecting airway management
* Refusal of consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Time to recovery of neuromuscular function (normalised train-of-four ratio ≥ 0.9) after sugammadex injection
Timeframe: From intravenous administration of sugammadex until achievement of normalized TOF ratio ≥ 0.9 (in seconds).